Published in final edited form as:

Physiol Behav. 2009 May 25; 97(2): 250–258. doi:10.1016/j.physbeh.2009.02.033.

Sex differences in psychopathology: Of gonads, adrenals and mental illness

Matia B. Solomon^{a,*} and James P. Herman^{a,b}

^a Department of Psychiatry, University of Cincinnati, Genome, Research Institute, Reading, OH 45237, United States

^b Department of Neuroscience, University of Cincinnati, Genome, Research Institute, Reading, OH 45237, United States

Abstract

Stress-related disorders such as anxiety and depression are disproportionately prevalent in women. Women are more likely to experience depression and anxiety disorders during periods of marked hormonal fluctuations, suggesting that gonadal hormones are involved in stress pathology. Depression and anxiety are both associated with aberrant secretion of glucocorticoids, which also show marked fluctuations across the reproductive cycle and in response to gonadal steroids. Thus, interactions between gonadal and stress hormones may play a major role in predisposing females to stress-related disease. The purpose of this brief review is to highlight preclinical data regarding the role of estrogens in depression and anxiety-like behaviors. While it is evident the exogenous estrogens modulate affective behavior in rodents, there is some disagreement in the literature, perhaps related to experimental designs that vary with respect to administration parameters and stress. Beneficial effects of estrogens on mood are most likely due to estrogen receptor (ER) β signaling. The antidepressant and anxiolytic effects of ER β are consistent with its role in attenuating glucocorticoid responses to stress, suggesting that estrogens, acting at ER β , may improve mood by suppressing glucocorticoid hyperactivity. However, additional studies demonstrate that ER β signaling in the hippocampus is sufficient to induce antidepressant and anxiolytic behaviors. Thus, ER β may improve mood via primary actions on hypothalamic (i.e., paraventricular nucleus) and/or extra-hypothalamic sites. Overall, the preclinical research suggests that selective ER modulators targeting ER β may be an attractive alternative or adjunct treatment to currently prescribed antidepressants or anxiolytics.

Keywords

17- β estradiol; Glucocorticoids; Depression; Corticotrophin releasing hormone; Estrogen receptors; Hypothalamic pituitary-adrenal axis; Serotonin; Forced swim test; Elevated plus maze; Open field; Anxiety

* Corresponding author. University of Cincinnati, Department of Psychiatry, Genome Research, Institute Bldg. E. Room 205, 2170 E. Galbraith Rd./ML-0506, Reading, OH 45237-1625, United States. matia.solomon@uc.edu (M.B. Solomon).

1. Introduction

Women are significantly more likely to suffer from affective disorders than men. Not surprisingly, female gonadal steroids are thought to play an important role in the sex difference in incidence. In the present review, we focus on the role of estrogens in the etiology of depression-like and anxiety-like behaviors in rodents. Here, we refer to estrogens as a class of hormones including estriol, 17- β estradiol (E_2) and estrone. Our primary focus is on the role of endogenous and exogenous (E_2) on mood-related behaviors in cohorts of females in varying hormonal states as it is the most abundant estrogen in premenopausal females and is the most studied. The current review is designed to: 1) summarize the current state of research on the role of E_2 and estrogen receptors (i.e., $ER\alpha$, $ER\beta$) on mood based on evidence from studies involving knockout mice, selective estrogen receptor agonists and antisense oligonucleotide techniques; 2) indicate possible mechanisms of E_2 interaction with stress processing, focusing on the hypothalamo-pituitary-adrenocortical axis (HPA axis); 3) discuss sex differences in depression-like and anxiety-like behaviors in rodents and indicate how different coping strategies and stress exposure regimens may influence the outcome of these studies and 4) discuss the applications of the preclinical data to future treatment strategies, possibly using estrogen receptors as therapeutic targets.

2. Estrogens modulate depression and anxiety-related behaviors

Depression and anxiety are often comorbid disorders resulting in psychological, physiological and behavioral symptoms, all of which can significantly impact health and well-being. Lifetime prevalence rates for depression and anxiety disorders (e.g., social phobia, obsessive compulsive disorder) are 20% and 12%, respectively [1–3]. Women are twice as likely to suffer from these disorders than men [4–6], suggesting that gonadal hormones and/or genetic sex are significant risk factors for development of pathologies.

Clinical data indicate that gonadal hormones have a significant impact on mood in women. Women are more likely to suffer from depression and anxiety during periods of marked hormonal fluctuations including the premenstrual, postpartum and perimenopausal periods, as reviewed in [7,8]. Symptoms of premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD) occur during the late luteal phase of the menstrual cycle when (E_2) and progesterone levels are low. During the postpartum period, the so called “pregnancy protection” on mood disappears, concomitant with a decline in E_2 levels [9–11]. Furthermore, incidence of mood disturbance increases as women progress toward menopause, corresponding to a period of falling E_2 levels [12]. The increased risk of affective disease during the menopausal period can occur despite no prior history of mood disorders [13]. These findings suggest two things: (a) the fluctuations of hormones are primary contributors to the onset of depression and anxiety-related symptoms in women and (b) within the context of normal physiology, the presence of E_2 may have a beneficial effect on mood. The therapeutic effects of E_2 on affective diseases are not universal, as there are several studies which report no change in mood with E_2 treatment [14–16]. Many factors likely contribute to the mixed effects of gonadal hormones on mood, including age, dosage and treatment regimen (i.e., combined E_2 and progesterone). Of note, depression and anxiety are complex, multi-factorial disorders and several important factors outside of gonadal

hormones influence the onset of psychopathology, including genetics, socio-cultural roles and importantly, environmental stressors. However, for the purpose of this review, we focus primarily on E₂ and stress as precipitating factors in psychopathology.

2.1. E₂ and depression-like behavior in rodents

There are a variety of rodent models that are suitable for studying depression-like behavior. One behavioral paradigm commonly used to test depression-like behavior or efficacy of antidepressants is the forced swim test (FST) [17–20]. Rodents exhibit active and passive behaviors in this paradigm: active behaviors include swimming, diving, headshakes and climbing, whereas immobility and/or floating are indicative of passive behaviors. Antidepressants modulate the display of certain behaviors within this task [18]. For instance, selective serotonin reuptake inhibitors (SSRIs) selectively increase swimming behaviors, whereas tricyclic antidepressants targeting catecholaminergic systems increase climbing behaviors. Largely as a result of antidepressant reversibility, the amount of time spent immobile is thought to indicate depression-like behavior.

Depression-like behavior in the FST varies as a function of the estrous cycle in rodents. For example, immobility in the FST is reduced in females in the proestrous phase of the cycle (marked by with high endogenous E₂) relative to females with lower E₂ as seen in the metestrous or diestrous phase [21,22]. In addition, in rats, depression-like behaviors are decreased during pregnancy [23,24] and increased upon withdrawal of hormones [25,26], analogous to the postpartum increases in depression observed in women. E₂ treatment attenuates enhanced immobility in the FST observed during a simulated post partum period [27], suggesting that exogenous E₂ mitigates depressive symptoms. Finally, total deficiency of estrogens and progestins with ovariectomy increases behavioral despair in an E₂ reversible manner [28–31], suggesting that the E₂ is necessary for appropriate regulation of mood.

In women, premenstrual syndrome (PMS) is characterized by a cluster of affective symptoms, including increased irritability, that occur during periods of decreased E₂. In a preclinical model of premenstrual irritability, animals are exposed to a resident intruder paradigm and aggression is monitored over the course of the estrous cycle [32]. Similar to what is observed in women, aggression increases in rodents during the metestrous phase of the cycle and this increase in aggressive behavior coincides with the increased immobility observed in the FST. Together these findings suggest that increased aggression is correlated with increased depression-like behavior within this animal model of premenstrual syndrome. Overall, the data cited above suggest that endogenous and exogenous E₂ decrease depression-like behavior in rodents. However, it is important to note that the beneficial effects of E₂ are not reproduced in all studies as some report increased depression-like behavior in the FST following E₂ administration [33]. The difference in E₂-mediated effects on depression-like behavior among some studies may depend on the dosage and duration of treatment.

2.2. E₂ and anxiety-like behaviors in rodents

There are also pronounced effects of gonadal steroids on anxiety-like behaviors. In rodents, tests designed to provoke anxiety-like behaviors typically use novel, innately threatening environmental stimuli. Being prey species, rodents have an innate aversion to open or brightly lit arenas, resulting in inhibition of exploratory and consummatory behaviors in tests such as the elevated plus maze (EPM) and open field. In addition, presence of unfamiliar conspecifics can produce withdrawal reactions in some animals, consistent with an anxiety-like response. Several studies report that proestrous females have greater open arm time in an EPM, enhanced exploratory activity in the open field and increased social interaction with conspecifics and decreased defensive marble burying relative to diestrous females and males [22,34–37], all of which are consistent with decreased anxiety-like behavior. However, not all studies are consistent with anxiolytic effects of endogenous or exogenous estrogens. Several studies report decreased activity and decreased central arm entries in proestrous or sexually receptive female rats and mice, suggestive of increased anxiety during periods of high E₂ [38–42]. Still others report no differences in open field behavior between proestrous and diestrous female hamsters [43]. The varied effects of endogenous E₂ on anxiety-like behaviors in intact females extend to studies with E₂ treatment in ovariectomized females. Several studies report decreased anxiety-like behaviors in the open field, EPM and social interaction in ovariectomized females treated with E₂ [44–46] while others report increased anxiety-like behavior in E₂ treated females during open field or EPM exposure [42,47,48].

Multiple factors contribute to the contrasting effects of E₂ on anxiety-like behavior, including species differences, time of day tested (i.e., early proestrus or late proestrus), lighting conditions, hormonal dosage, method of administration and previous exposure to other behavioral tasks. The last point is particularly important, since multiple exposures to a variety of behavioral tasks may decrease fear of novelty and subsequently decrease anxiety-like behaviors. Furthermore, one must keep in mind that other hormones in addition to E₂ change over the course of the estrous cycle and with ovariectomy, including progesterone and corticosterone. Both progesterone and corticosterone independently influence depression and anxiety-like behaviors in rodents [44,49,50]. Thus, it may be difficult to completely isolate the effects of E₂ on affective behaviors from these other hormones. Finally, it has been proposed that the E₂ mediated actions on affective behavior in rodents may be due to increased activity and overall arousal [51]. Given that many of the behavioral assays for depression and anxiety rely on locomotion, it is important to consider use of tests that are less dependent upon this endpoint (e.g., anhedonia) for assessment of depression-like behavior.

2.3. Activation of estrogen receptors modulates depression and anxiety-like behaviors

The biological effects of estrogens are mediated by binding to two intracellular estrogen receptors (ER α and ER β). Ligand binding leads to dimerization and translocation to the nucleus, where activated ERs interact with estrogen response elements or DNA-binding proteins such as activator protein-1 or specificity protein-1, resulting in changes in gene transcription [52]. Estrogens also interact with membrane estrogen receptors (i.e., GPR30), triggering activation of signaling cascades (e.g., mitogen-activated protein kinase) [53].

While the distribution of central ER α and ER β is similar between females and males, mRNA and protein expression levels in some brain regions are higher in females [54,55]. Immunohistochemical and in situ hybridization studies indicate both overlapping and distinct patterns of central ER α and ER β expression in both female and male brains. For example, ER α is abundantly expressed in areas regulating reproduction function and energy homeostasis, including the medial preoptic area, arcuate nucleus of the hypothalamus and ventromedial hypothalamus in both females and males [54–57]. In contrast, ER β predominates in areas implicated in regulation of mood and HPA axis activity including the hippocampus, dorsal raphe nucleus, medial prefrontal cortex and paraventricular nucleus of the hypothalamus (PVN) [57–59]. There are several other regions where both receptors are co-localized, including the medial amygdala, bed nucleus of stria terminalis and medial preoptic area [60], suggesting the possibility of intracellular interaction between the two receptor subtypes within these regions.

Our understanding of the functional roles of these receptor subtypes has been advanced by genetic, pharmacological and molecular techniques. For example, male and female ER α KO mice have decreased reproductive function and increased body weight relative to wild-type controls [61,62]. Furthermore, propylpyrazoletriol (PPT), a compound with high affinity to ER α , facilitates sexual receptivity and proceptivity in females [63–65], whereas down-regulation of central ER α by antisense oligonucleotides attenuates sexual receptivity [66].

In contrast to ER α , central ER β does not appear to be critical for reproductive function. However, several studies support a selective role for ER β in mediating affective behaviors in rodents. Depression and anxiety-like behaviors in the FST, EPM and open field are markedly increased in female ER β KO relative to wild-type females [67,68] but not female ER α KO mice [68]. Further, the antidepressant and anxiolytic effects of E₂ and diarylpropionitrile (DPN), an agonist selective for ER β , are absent in female ER β KO mice [36,69,70]. The beneficial effects of ER β agonists are also evident in gonadectomized males [71]. These findings suggest that E₂ signaling through this receptor subtype is important for modulating depression-like and anxiety-like behaviors in both sexes. It is important to note that the majority of studies that have evaluated the efficacy of ER β agonists as antidepressants and/or anxiolytics have utilized gonadectomized females and males. A recent study by Patisaul and colleagues found that DPN at several doses was ineffective as an anxiolytic in intact males [158]. These findings raise some concern about the usefulness of ER β agonists in intact animals and suggest that the therapeutic value of these compounds may be dependent upon the gonadal status of the animal. Nonetheless, the preclinical data overwhelmingly suggest that these compounds may be beneficial in the treatment of mood disorders. Unlike ER β , the role of ER α in mediating anxiety and depression-like behavior is less clear. Some studies report increased anxiety-like behaviors in ovariectomized females following PPT administration [62] whereas others find no effects of the ER α agonist [63].

The therapeutic effects of ER β on anxiety and depression may be due to interactions with the serotonergic system. ER β is heavily expressed in the dorsal raphe and is co-localized with tryptophan hydroxylase 2 (TPH₂) in males [59]. Administration of E₂ increases expression of TPH₂ in the dorsal raphe in females [72], suggesting a functional role of ER β in this region. Finally, serotonin content is decreased in the bed nucleus of the stria

terminalis and hippocampus of female ER β KO mice relative to controls [67], regions believed to be of importance in mood regulation. Together these findings suggest that the ER β and serotonin systems may interact to regulate mood in both females and males. Consistent with the preclinical findings, combination therapy with E₂ may improve the efficacy of selective serotonin reuptake inhibitors (SSRIs) on mood in women [73].

Central E₂ administration modulates mood in female rodents. For example, E₂ administered directly to the hippocampus, medial amygdala or intra-amygdala area decreases immobility in the FST. E₂ administration within these regions also decreases anxiety-like behaviors in the EPM and open field [44,74]. Administration of DPN to the hippocampus decreases depression and anxiety-like behaviors, suggesting that ER β signaling within this region is sufficient for improved mood in females [74]. In addition, intracerebroventricular administration of antisense oligodeoxynucleotides (AS-ODNs) against ER β increases depression-like and anxiety-like behaviors in the FST, open field and EPM [66]. Within this study, central AS-ODNs decreased ER β immunoreactivity in the hippocampus suggesting that ER β signaling in this region is necessary for the E₂-mediated antidepressant and anxiolytic effects. However, other regions known to modulate affect and contain ER β such as the bed nucleus of the stria terminalis, medial prefrontal cortex, amygdala and dorsal raphe were not assessed, leaving open the possibility that decreased ER β within these regions may also play a role in the increased depression-like and anxiety-like behaviors.

Middle-aged (12 months) and older (24 months) females have decreased ER β expression in several regions including the hippocampus, dorsal raphe, nucleus accumbens and basolateral amygdala compared with young (10 weeks) female rats [75]. Decreased central ER β immunoreactivity within these regions in middle aged and older females may underlie the reported increase in depression-like or anxiety-like behaviors associated with aging in some rodents [76]. These data suggest that ER β may affect mood via interactions with circuits controlling emotional responses and stress. Future studies are needed to determine the necessity of ER β signaling in other key areas known to modulate mood, such as the central amygdala, medial prefrontal cortex and bed nucleus of the stria terminalis.

3. Gonadal hormones modulate stress responses

3.1. Stress, the hypothalamic pituitary-adrenal axis and affective disorders

Life stress exposure plays a significant role in the pathophysiology of both depression and anxiety. Of note, dysregulation of cortisol, a key stress hormone, is linked with the onset and/or severity of a variety of affective diseases, including bipolar disorder, anxiety, post-traumatic stress disorder and major depression [77–79]. Glucocorticoids are the principle output of the hypothalamo-pituitary-adrenocortical axis, a system integral to maintenance of homeostasis. Activation of the HPA axis by external stimuli (e.g., stress) triggers a series of neuroendocrine responses. Real or perceived stressors stimulate hypothalamic neurons in the medial parvocellular PVN. Once activated these neurons synthesize and secrete ACTH secretagogues (corticotrophin releasing hormone (CRH) and arginine vasopressin (AVP)), which stimulate pituitary corticotrophs, causing release of adrenocorticotrophic hormone (ACTH) into systemic circulation. ACTH then stimulates the adrenal cortex, resulting in the synthesis and release of glucocorticoids (cortisol in humans, corticosterone

in rats). Glucocorticoids, the end product of this system, exert negative feedback at the level of the pituitary, hypothalamus and extra-hypothalamic sites including the hippocampus and medial prefrontal cortex, thereby limiting prolonged activation of this system, as reviewed in [80] (see Fig. 1). Elevated glucocorticoids seen in depression are believed to result from deficient negative feedback, resulting in increased glucocorticoid signaling at the level of the brain. It is thought that central glucocorticoids promote depression-like behavior, triggering clinical trials of the antidepressant efficacy of glucocorticoid receptor antagonists [81].

3.2. Stress, sex, gonadal hormones and depression-like and anxiety-like behaviors

Stress increases depression and anxiety-like behaviors in both male and female rodents. For example, social defeat, chronic mild stress, repeated restraint or repeated footshock stress all induce behavioral changes characteristic of depression-like and anxiety-like behavior including 1) increased immobility in the FST [82]; 2) decreased sucrose intake [82–84]; 3) decreased body weight or attenuated body weight gain [85,86]; and 4) decreased social behavior and decreased exploratory behavior in the open field and EPM [82,87,88]. The varied effects of E₂ on affect in females may be related to prior stress or testing history. For example, stress affects performance in females on certain behavioral tasks, including learned helplessness [89–91] and classical eye blink conditioning [92,93], in accordance with gonadal hormone status. The reported decrease in depression-like and anxiety-like behaviors during period of higher endogenous E₂ disappears if females are stressed prior to testing. For example, previous studies have found that administration of inescapable shock or restraint stress prior to eyeblink conditioning significantly impairs learning in females during the proestrous phase of the cycle relative to estrous and diestrous females [92,93]. Without prior stress, females in the proestrous phase perform better on learning tasks than other females, suggesting context-dependent effects of endogenous E₂. Consistent with this finding, others have found that females are more vulnerable to stress-induced depression-like behaviors during the diestrous 2 phase versus those in the estrous phase [91]. These findings suggest that the combination of stress hormones and higher fluctuating E₂ are particularly disruptive on affect, learning and memory.

There are striking sex difference in depression-like and anxiety-like behaviors. However, no consensus on the nature of male–female differences has emerged. Previous inescapable footshock stress, repeated restraint (21 days) or periodic maternal deprivation increases subsequent depression and anxiety-like behaviors as assessed by FST, EPM and open field in males but not in females [94–100]. However, using different paradigms, others note increased depression-related behaviors in the FST and anxiety-like behaviors in the open field in females relative to males [101–103]. These conflicting findings of sex and stress on performance are likely due to several design issues, including consideration of estrous cycle staging. For example, following social defeat stress, it appears that female Syrian hamsters are relatively insensitive to defeat-induced depression-like behavior [87]. However, when the estrous cycle is considered, females defeated in diestrous and later tested in proestrous are more likely to display depression-like behavior than their metestrous counterparts [43]. Notably, there was no difference in depression-like behavior or anxiety-like behavior in proestrous and diestrous females without stress exposure. These findings underscore the importance of understanding how elevated stress hormones combined with higher and/or

fluctuating E₂ levels may disproportionately predispose females towards depression-like or anxiety-like behaviors. In addition, the nature of experimental paradigms clearly impact outcome in behavioral studies of sex differences. Females are thought to perform better on active avoidance or escape tasks [104,105], whereas males perform better on passive avoidance tasks [106,107]. Thus, considering both the hormonal status of the female and the type of task at hand can significantly impact the outcome of stress-induced effects on performance. Given that stress and gonadal hormones are both implicated in the etiology of affective diseases, it is important to understand how these two factors interact to produce alterations in mood.

3.3. Endogenous E₂ modulates HPA axis responses

An abundance of data indicates sex and estrous cycle differences in HPA axis responsivity to acute stress in rodents. For example, cycling female rats have higher basal and stress-induced corticosterone secretion in response to a number of stressors including ether, lipopolysaccharide administration, cocaine, noise and restraint [108–111]. Furthermore, proestrous females exhibit greater HPA axis responses to an acute stressor relative to males and diestrous females [111–114] (however see [115]). Overall, it appears intact, cycling females have higher basal and stress-induced ACTH and/or corticosterone responses relative to males, at least in part due to E₂ and/or progesterone. Pregnancy and lactation also alter HPA axis responsivity to acute stressors. Both are associated with decreased HPA activity in response to a variety of stressors [116–118]. Suppressed stress responses during pregnancy occur despite higher endogenous E₂ levels in pregnancy. Reduced stress responses during lactation are likely associated with oxytocin, which inhibits the HPA axis [119,120]. Notably, suckling in women increases plasma oxytocin levels and decreases ACTH and cortisol secretion [121]. Taken together these findings indicate that the influence of gonadal hormones on HPA axis tone is dependent upon the reproductive context of the female.

3.4. Exogenous E₂ modulates HPA axis responses

Hormonal replacement studies have presented contrasting findings concerning the effects of E₂ on neuroendocrine responses to acute stress. These contrasting findings are likely due to the dosage and/or hormonal regimens used for E₂ administration. Past studies demonstrate that supraphysiological doses of E₂ increase ACTH and/or corticosterone secretion in gonadectomized males and females [88,112,122,123]. In contrast, work from our laboratory and others find that physiological doses of E₂ injections decrease ACTH and/or corticosterone responses to acute stressors [30,124–126].

Given that ERs are located in the pituitary, hypothalamus and extra-hypothalamic HPA regulatory sites (i.e., hippocampus, prefrontal cortex), it is likely that E₂ impacts HPA axis activity at multiple levels. Data from our laboratory suggests that a potential mechanism by which E₂ regulates HPA axis activity is by enhancement of adrenal sensitivity [124]. Physiologically relevant E₂ pellets or injections consistently decrease ACTH responses to restraint or novelty stress. The dampened ACTH response in E₂ treated females is accompanied by increased plasma corticosterone, indicating that E₂ mediated HPA stimulation is due to adrenal gland hypersensitivity to ACTH. A similar effect occurs in castrated males treated with E₂ [123].

Several studies report that proestrous females and gonadectomized animals treated with E₂ increase CRH heteronuclear mRNA, CRH protein expression [88,127–129] and AVP mRNA expression [88,129] compared with controls. These findings suggest the E₂ may interact directly with CRH and AVP to regulate central HPA axis drive. This fact is plausible given that there is a partial estrogen response element in the promoter region of the CRH gene [130]. However, other studies do not report enhanced CRH expression following E₂, perhaps due to differences in duration and method of E₂ administration [124,131].

Physiologically relevant doses of E₂ alone or in combination with progesterone attenuate stress-induced activation of frontal cortex, hippocampal and PVN neurons in response to a number of acute stressors [28,83,124,132]. The decrease in central stress responsivity following physiologically relevant doses of E₂ may underlie the antidepressant and anxiolytic effects of E₂. Consistent with this observation, one group reports decreased central stress responsivity, as measured by *c-fos* expression, following acute forced swim test exposure in E₂ treated females in regions known to regulate HPA axis tone, including the anterior cingulate, hippocampus, basolateral amygdala and PVN. Changes in stress reactivity were accompanied by decreased depression-like behavior in the FST in this study [28].

As a whole, the findings presented thus far suggest that the varied effects of exogenous E₂ on mood may be in part due to interactions with HPA axis responsiveness. These contrasting effects of E₂ on mood and HPA axis activity are likely due to differential activation of ERs. In accord with this possibility, systemic or PVN administration of DPN pellets decrease ACTH, corticosterone and PVN *fos* mRNA in response to stress, whereas E₂ and PPT pellets increase these responses [133,134]. E₂ binds with similar affinity to both receptor subtypes [133], suggesting that excitatory vs. inhibitory effects of E₂ on central and neuroendocrine stress responses may depend on whether ER α or ER β containing neurons are active.

3.5. Gonadal hormones modulate chronic stress responses

In general, the data regarding sex differences in HPA axis responsivity to chronic stress are mixed. Some studies report increased corticosterone responses in females [135–137] or increased responses in males [102] while others find no sex difference [138]. A recent study reported greater chronic stress-induced increases in corticosterone in female rats relative to male rats, but greater stress-induced hypothalamic CRH mRNA in males compared with females [136,138]. Within this study, CRH mRNA expression was substantially higher in control females than males, suggesting a potential ceiling effect. This finding may explain the increased corticosterone responses in females under both basal and stress conditions. Furthermore, within this study, both females and males display anhedonia, a common symptom of depression, following chronic stress. Thus, at least with some chronic stress models, both females and males are susceptible to stress-induced depression-like behavior.

Physiologically relevant E₂ administration during chronic stress decreases central stress responsivity. For example, cyclic E₂ replacement protects females from chronic stress-induced increases in PVN activation [139,140]. Cyclic E₂ treatment also increases medial prefrontal cortex activity during chronic stress [140], suggesting engagement of an upstream

inhibitor of the HPA axis (see Fig. 2). This finding is particularly important, as decreased neural activity within this region is associated with increased depression in humans [141]. Moreover, these data suggest that the deleterious effects of chronic stress on HPA axis function and perhaps behavior may be related to stress-induced reductions in circulating E₂ [137]. A recent report suggests that restraint stress decreases the antidepressive and anxiolytic effects of systemic E₂ in females [30]. Importantly, women with lower E₂ reportedly are more likely to be depressed [142]. Thus, it is possible that chronic stress-induced interference with E₂ mediated signaling may increase the risk for development of psychopathology in women.

While we have focused primarily on how gonadal hormones modulate HPA axis tone, there is a reciprocal connection between the hypothalamic pituitary-gonadal (HPG) and HPA axes. For example, chronic stress is associated with decreased reproductive function in women [143,144]. Increased CRH or glucocorticoids may impact HPG function via inhibition of hypothalamic gonadotropin releasing hormone (GnRH) neurons. Decreased central GnRH release may subsequently diminish pituitary release of gonadotropins (lutening hormone and follicle stimulating hormone) thereby reducing the amount of estrogens and progestins from the ovaries and androgens from the testes.

There are only a few reports concerning the impact of chronic stress on estrous cyclicity in female rodents. These studies indicate that chronic stress can lengthen cycles or stall females in a particular stage of the cycle [135,138,145,146]. The stress-induced disruption of the cycle may be due to decreased E₂ concentrations [137]. Stress-induced impairment in the HPG axis is not exclusive to females as subordinate male rats have decreased testosterone levels compared with their dominant counterparts in a social stress paradigm [147]. In keeping with a protective effect of gonadal hormones on mood, men with significantly lower testosterone are more likely to be depressed relative to those with higher levels [148]. Likewise, testosterone reduces anxiety-like behavior in castrated male rodents [149]. Taken together these findings suggest that stress hormones may impact mood by suppressing gonadal hormones.

There are a few studies that have examined the effects of exogenous glucocorticoids or chronic stress on ER β mRNA and protein expression in the PVN [139,150,151]. Overall, these studies find that glucocorticoids increase ER β expression in the PVN, suggesting that chronic stress-induced increase in PVN ER β expression may be a protective mechanism to offset sustained activation of the HPA axis [139]. This hypothesis is consistent with the known inhibitory effects of ER β on the HPA axis [133]. Clearly, additional studies examining the effects of acute or chronic stress on ER α or ER β expression in limbic regions is warranted.

4. Usefulness of behavioral assays for modeling human psychopathology

One of the biggest issues concerning preclinical research is the degree to which it models clinical pathology. Overall the traditional behavioral assays for assessing depression-like and anxiety-like behaviors (i.e., FST, EPM, open field) generally find that females with lower, declining or deficient E₂ levels (as seen during metestrous, simulated post partum and

ovariectomized conditions, respectively) increase depression-like or anxiety-like behaviors [21,26,31,35]. These findings are comparable to the reported increase in mood disturbance during the premenstrual, postpartum and menopausal periods in women. Therefore, when comparing females in differing hormonal states, these tasks are reliable. However, the well-documented sex difference in clinical depression and anxiety is reversed in these preclinical models. Clinical data indicate that twice the number of women suffer from both depression and anxiety disorders than men. If one relies upon the principles of these commonly used behavioral assays, then at least underline baseline conditions in many studies, depression and anxiety-like behaviors are less evident in female than male rodents. For example, in the FST female rodents appear to be more active relative to males as they display more swimming and climbing and less immobility [22,152–154]. Furthermore, females tend to be more active compared with males and are more likely to explore open arms and have more central arm entries, suggestive of decreased anxiety-like behavior [22,51,155,156].

If basic neurobiological studies are going to advance our knowledge concerning human psychopathology, it is necessary to develop models that are truly reflective of sex differences present in clinical pathology. What is apparent is that males and females might respond differently to similar stress conditions dependent upon the phase of the estrous cycle or the context of the testing conditions. A previous theory by Morgan and colleagues [51] posits that estrogens modulate female behavior in accordance with the appraisal of the situation. A possible role of context in estrogen signaling has important implications for interpretation of behavioral data. For example, a female rat in proestrus or estrus might decrease anxiety-like behavior in the EPM and open field as a consequence of increased locomotion, perhaps associated with seeking of a mate. In this case, the reproductive drive may override innate fear of open spaces. E_2 may also increase activity in safe environments while increasing vigilance and attention in potentially threatening environments, perhaps explaining some of the inconsistencies in studies on E_2 -mediated effects on anxiety and depression-like behaviors. In addition, females and males may respond differently to the same stressors, as what is stressful to males may not be as stressful for females [157]. Therefore, stress models that are more relevant to the types of stressors that males and females are likely to endure in their natural environment are needed.

It is also worth noting that a number of distinct behaviors are manifest during tests for depression- and anxiety-like behavior. Focusing only on the more common measures may reduce the likelihood of detecting important changes in behavior. Case in point, in the EPM, duration of time spent in the open and closed arms are routinely reported as indices of decreased and increased anxiety-like behavior, respectively. There are a variety of other behaviors exhibited in the EPM including head dips, rearing, increased fecal excretion and excessive grooming, which have important implications for the interpretation of behavior. Furthermore, simply reporting increased immobility or decreased immobility in the FST may not be sufficient to explain all aspects of depression-related behaviors, particularly given that certain antidepressants selectively modify different active behaviors within the FST [18,28].

5. Concluding remarks

Depression and anxiety are debilitating disorders that significantly impact quality of life. This review highlights relevant preclinical data on the role of endogenous and exogenous E₂ on depression and anxiety-like behaviors as well as HPA axis responsiveness. The varied effects of E₂ on HPA axis tone and mood are likely due to differential activation of the ERs. Administration of supraphysiological doses of E₂ or ER α agonists increase HPA axis tone, which may be an underlying factor in the reported increased depression and anxiety-like behaviors [122,133,134]. In contrast, physiologically relevant doses of E₂ or ER β agonists decrease HPA axis output concomitant with decreases in both depression and anxiety-like behaviors [28,63,133]. Given that stress precipitates many psychopathologies that predominate in women, it is critical to understand how stress and gonadal hormones interact to regulate mood. Furthermore, it is important to consider stress interference with central E₂ mediated function. Based on the considerable amount of data suggesting a beneficial effect of E₂ on mood, it is puzzling that so many premenopausal women with presumably normal ovarian functioning suffer from stress-related psychopathologies. On the basis of previous research, it is possible that stress decreases the beneficial effects of exogenous E₂ on mood [30] and may even increase the likelihood for the development of depression-like and anxiety-like behaviors during periods of higher fluctuating endogenous E₂ levels [43,91,92].

The literature strongly suggests that combination of increased stress sensitivity and constant fluctuations of ovarian hormones throughout the reproductive cycle (resulting in periodic loss of the protective effects of estrogens) predisposes women to depression and anxiety disorders. Given that estrogens positively modulate important transmitter systems modulating mood and reward (i.e., serotonin, dopamine) [73], periodic E₂ withdrawal consequent to stress, parturition, and even the normal cycle may make women more sensitive to stress-related psychopathologies.

The past decade has yielded important advances in the understanding of the role of estrogens in mood. With some caveats, the data generally support the hypothesis that E₂ has beneficial effects on depression or anxiety-like behaviors in rodents. Inconsistencies in the literature are associated with variability in behavioral assays and treatment designs, likely reflecting an exquisite sensitivity of the brain to both high and low levels of circulating estrogens and their interactions with other factors, such as stress hormones. Nonetheless, based on the overwhelming data supporting a therapeutic effect of selective estrogen receptor modulators (SERMS) aimed at ER β , it is likely that treatment strategies aimed at this receptor subtype may prove a useful therapy for affective disorders.

Both basic and clinical researchers are driven to understand the profound sex difference in the incidence of depression and anxiety. Because both depression and anxiety are complex disorders, it is likely that several factors outside of gonadal hormones interact to produce psychopathology in vulnerable individuals. For example, men also possess ER β and can synthesize E₂, yet have lower instances of depression. It is apparent that at the bench we can eliminate the female-biased increase in depression-like and anxiety-like behaviors with physiological E₂ and ER β agonists. With continued medical advances, one can only hope that we will reduce the increased incidence of depression and anxiety disorders in women. In

that light, ER β selective compounds either alone or perhaps in combination with currently prescribed antidepressants and/or anxiolytics may be an important new treatment method for affective diseases in women and perhaps men.

Acknowledgements

The authors would like to thank Dr. Michelle Foster for assistance with illustrations. This work was supported by MH069725 to JPH and MBS and AG12962 to JPH.

References

1. Strine TW, et al. Depression and anxiety in the United States: findings from the 2006 Behavioral Risk Factor Surveillance System. *Psychiatr Serv.* 2008; 59(12):1383–90. [PubMed: 19033164]
2. Kessler RC, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. *Arch Gen Psychiatry.* 1994; 51(1):8–19. [PubMed: 8279933]
3. Blazer DG, et al. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. *Am J Psychiatry.* 1994; 151(7):979–86. [PubMed: 8010383]
4. Earls F. Sex differences in psychiatric disorders: origins and developmental influences. *Psychiatr Dev.* 1987; 5(1):1–23. [PubMed: 3601929]
5. Bekker MH, van Mens-Verhulst J. Anxiety disorders: sex differences in prevalence, degree, and background, but gender-neutral treatment. *Gend Med.* 2007; 4(Suppl B):S178–93. [PubMed: 18156102]
6. Breslau N, Chilcoat H, Schultz LR. Anxiety disorders and the emergence of sex differences in major depression. *J Gend Specif Med.* 1998; 1(3):33–9. [PubMed: 11279862]
7. Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? *Biol Psychiatry.* 1998; 44(9):798–811. [PubMed: 9807636]
8. Douma SL, et al. Estrogen-related mood disorders: reproductive life cycle factors. *ANS Adv Nurs Sci.* 2005; 28(4):364–75. [PubMed: 16292022]
9. Dean C, Kendell RE. The symptomatology of puerperal illnesses. *Br J Psychiatry.* 1981; 139:128–33. [PubMed: 7306750]
10. Stowe ZN, Nemeroff CB. Women at risk for postpartum-onset major depression. *Am J Obstet Gynecol.* 1995; 173(2):639–45. [PubMed: 7645646]
11. Hendrick V, Altshuler LL, Suri R. Hormonal changes in the postpartum and implications for postpartum depression. *Psychosomatics.* 1998; 39(2):93–101. [PubMed: 9584534]
12. Tangen T, Mykletun A. Depression and anxiety through the climacteric period: an epidemiological study (HUNT-II). *J Psychosom Obstet Gynaecol.* 2008; 29(2):125–31. [PubMed: 18484441]
13. Freeman EW, et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. *Arch Gen Psychiatry.* 2006; 63(4):375–82. [PubMed: 16585466]
14. Iatrakis G, et al. Psychosomatic symptoms of postmenopausal women with or without hormonal treatment. *Psychother Psychosom.* 1986; 46(3):116–21. [PubMed: 3628680]
15. Morrison MF, et al. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. *Biol Psychiatry.* 2004; 55(4):406–12. [PubMed: 14960294]
16. Hays J, et al. Effects of estrogen plus progestin on health-related quality of life. *N Engl J Med.* 2003; 348(19):1839–54. [PubMed: 12642637]
17. Fuxe K, et al. Mapping of glucocorticoid receptor immunoreactive neurons in the rat tel- and diencephalon using a monoclonal antibody against rat liver glucocorticoid receptor. *Endocrinology.* 1985; 117(5):1803–12. [PubMed: 4042964]
18. Lucki I, O'Leary OF. Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. *J Clin Psychiatry.* 2004; 65(Suppl 4):11–24. [PubMed: 15046537]

19. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. *Behav Pharmacol.* 1997; 8(6-7):523-32. [PubMed: 9832966]
20. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. *Neurosci Biobehav Rev.* 2005; 29(4-5):547-69. [PubMed: 15893822]
21. Contreras CM, et al. Lateral septal neuronal firing rate increases during proestrus in the rat. *Physiol Behav.* 2000; 68(3):279-84. [PubMed: 10716536]
22. Frye CA, Walf AA. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. *Horm Behav.* 2002; 41(3):306-15. [PubMed: 11971664]
23. Molina-Hernandez M, Tellez-Alcantara NP. Antidepressant-like actions of pregnancy, and progesterone in Wistar rats forced to swim. *Psychoneuroendocrinology.* 2001; 26(5):479-91. [PubMed: 11337132]
24. Frye CA, Walf AA. Hippocampal 3alpha,5alpha-THP may alter depressive behavior of pregnant and lactating rats. *Pharmacol Biochem Behav.* 2004; 78(3):531-40. [PubMed: 15251262]
25. Suda S, et al. A postpartum model in rat: behavioral and gene expression changes induced by ovarian steroid deprivation. *Biol Psychiatry.* 2008; 64(4):311-9. [PubMed: 18471802]
26. Stoffel EC, Craft RM. Ovarian hormone withdrawal-induced "depression" in female rats. *Physiol Behav.* 2004; 83(3):505-13. [PubMed: 15581673]
27. Galea LA, Wide JK, Barr AM. Estradiol alleviates depressive-like symptoms in a novel animal model of post-partum depression. *Behav Brain Res.* 2001; 122(1):1-9. [PubMed: 11287071]
28. Rachman IM, et al. Estrogen alters behavior and forebrain c-fos expression in ovariectomized rats subjected to the forced swim test. *Proc Natl Acad Sci U S A.* 1998; 95(23):13941-6. [PubMed: 9811905]
29. Walf AA, Rhodes ME, Frye CA. Antidepressant effects of ERbeta-selective estrogen receptor modulators in the forced swim test. *Pharmacol Biochem Behav.* 2004; 78(3):523-9. [PubMed: 15251261]
30. Walf AA, Frye CA. Antianxiety and antidepressive behavior produced by physiological estradiol regimen may be modulated by hypothalamic-pituitary-adrenal axis activity. *Neuropsychopharmacology.* 2005; 30(7):1288-301. [PubMed: 15756306]
31. Estrada-Camarena E, Fernandez-Guasti A, Lopez-Rubalcava C. Antidepressant-like effect of different estrogenic compounds in the forced swimming test. *Neuropsychopharmacology.* 2003; 28(5):830-8. [PubMed: 12637949]
32. Schneider T, Popik P. Increased depressive-like traits in an animal model of premenstrual irritability. *Horm Behav.* 2007; 51(1):142-8. [PubMed: 17049520]
33. Galea LA, et al. High levels of estradiol impair spatial performance in the Morris water maze and increase 'depressive-like' behaviors in the female meadow vole. *Physiol Behav.* 2002; 77(2-3):217-25. [PubMed: 12419397]
34. Marcondes FK, et al. Estrous cycle influences the response of female rats in the elevated plus-maze test. *Physiol Behav.* 2001; 74(4-5):435-40. [PubMed: 11790402]
35. Frye CA, Petralia SM, Rhodes ME. Estrous cycle and sex differences in performance on anxiety tasks coincide with increases in hippocampal progesterone and 3alpha,5alpha-THP. *Pharmacol Biochem Behav.* 2000; 67(3):587-96. [PubMed: 11164090]
36. Walf AA, et al. Proestrous compared to diestrous wildtype, but not estrogen receptor beta knockout, mice have better performance in the spontaneous alternation and object recognition tasks and reduced anxiety-like behavior in the elevated plus and mirror maze. *Behav Brain Res.* 2009; 196(2):254-60. [PubMed: 18926853]
37. Frye CA, Paris JJ, Rhodes ME. Exploratory, anti-anxiety, social, and sexual behaviors of rats in behavioral estrus is attenuated with inhibition of 3alpha,5alpha-THP formation in the midbrain ventral tegmental area. *Behav Brain Res.* 2008; 193(2):269-76. [PubMed: 18590775]
38. Diaz-Veliz G, et al. Gender, estrous cycle, ovariectomy, and ovarian hormones influence the effects of diazepam on avoidance conditioning in rats. *Pharmacol Biochem Behav.* 2000; 66(4):887-92. [PubMed: 10973530]

39. Mora S, Dussaubat N, Diaz-Veliz G. Effects of the estrous cycle and ovarian hormones on behavioral indices of anxiety in female rats. *Psychoneuroendocrinology*. 1996; 21(7):609–20. [PubMed: 9044444]
40. Pare WP, Redei E. Sex differences and stress response of WKY rats. *Physiol Behav*. 1993; 54(6): 1179–85. [PubMed: 8295961]
41. Diaz-Veliz G, et al. Influence of the estrous cycle, ovariectomy and estradiol replacement upon the acquisition of conditioned avoidance responses in rats. *Physiol Behav*. 1989; 46(3):397–401. [PubMed: 2623060]
42. Morgan MA, Pfaff DW. Estrogen's effects on activity, anxiety, and fear in two mouse strains. *Behav Brain Res*. 2002; 132(1):85–93. [PubMed: 11853861]
43. Solomon MB, Karom MC, Huhman KL. Sex and estrous cycle differences in the display of conditioned defeat in Syrian hamsters. *Horm Behav*. 2007; 52(2):211–9. [PubMed: 17555756]
44. Frye CA, Walf AA. Estrogen and/or progesterone administered systemically or to the amygdala can have anxiety-, fear-, and pain-reducing effects in ovariectomized rats. *Behav Neurosci*. 2004; 118(2):306–13. [PubMed: 15113256]
45. Bowman RE, Ferguson D, Luine VN. Effects of chronic restraint stress and estradiol on open field activity, spatial memory, and monoaminergic neurotransmitters in ovariectomized rats. *Neuroscience*. 2002; 113(2):401–10. [PubMed: 12127097]
46. McCarthy MM, Schwartz-Giblin S, Wang SM. Does estrogen facilitate social behavior by reducing anxiety? *Ann N Y Acad Sci*. 1997; 807:541–2. [PubMed: 9071393]
47. Leret ML, Molina-Holgado F, Gonzalez MI. The effect of perinatal exposure to estrogens on the sexually dimorphic response to novelty. *Physiol Behav*. 1994; 55(2):371–3. [PubMed: 8153180]
48. Morgan MA, Pfaff DW. Effects of estrogen on activity and fear-related behaviors in mice. *Horm Behav*. 2001; 40(4):472–82. [PubMed: 11716576]
49. Myers B, Greenwood-Van Meerveld B. Corticosteroid receptor-mediated mechanisms in the amygdala regulate anxiety and colonic sensitivity. *Am J Physiol Gastrointest Liver Physiol*. 2007; 292(6):G1622–1629. [PubMed: 17347454]
50. Brummelte S, Pawluski JL, Galea LA. High post-partum levels of corticosterone given to dams influence postnatal hippocampal cell proliferation and behavior of offspring: a model of post-partum stress and possible depression. *Horm Behav*. 2006; 50(3):370–82. [PubMed: 16780843]
51. Morgan MA, Schulkin J, Pfaff DW. Estrogens and non-reproductive behaviors related to activity and fear. *Neurosci Biobehav Rev*. 2004; 28(1):55–63. [PubMed: 15036933]
52. Paech K, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. *Science*. 1997; 277(5331):1508–10. [PubMed: 9278514]
53. Filardo EJ, et al. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. *Mol Endocrinol*. 2002; 16(1):70–84. [PubMed: 11773440]
54. Shughrue PJ, Bushnell CD, Dorsa DM. Estrogen receptor messenger ribonucleic acid in female rat brain during the estrous cycle: a comparison with ovariectomized females and intact males. *Endocrinology*. 1992; 131(1):381–8. [PubMed: 1612018]
55. Orikasa C, Sakuma Y. Sex and region-specific regulation of oestrogen receptor beta in the rat hypothalamus. *J Neuroendocrinol*. 2004; 16(12):964–9. [PubMed: 15667451]
56. Arteaga-Silva M, et al. Effects of castration and hormone replacement on male sexual behavior and pattern of expression in the brain of sex-steroid receptors in BALB/c AnN mice. *Comp Biochem Physiol A Mol Integr Physiol*. 2007; 147(3):607–15. [PubMed: 17292648]
57. Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. *J Comp Neurol*. 1997; 388(4):507–25. [PubMed: 9388012]
58. Blurton-Jones M, Tuszyński MH. Estrogen receptor-beta colocalizes extensively with parvalbumin-labeled inhibitory neurons in the cortex, amygdala, basal forebrain, and hippocampal formation of intact and ovariectomized adult rats. *J Comp Neurol*. 2002; 452(3):276–87. [PubMed: 12353223]

59. Nomura M, et al. Differential distribution of estrogen receptor (ER)-alpha and ER-beta in the midbrain raphe nuclei and periaqueductal gray in male mouse: predominant role of ER-beta in midbrain serotonergic systems. *Neuroscience*. 2005; 130(2):445–56. [PubMed: 15664701]
60. Shughrue PJ, Scrimo PJ, Merchenthaler I. Evidence for the colocalization of estrogen receptor-beta mRNA and estrogen receptor-alpha immunoreactivity in neurons of the rat forebrain. *Endocrinology*. 1998; 139(12):5267–70. [PubMed: 9832469]
61. Couse JF, et al. Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) null mice reveals hypergonadism and endocrine sex reversal in females lacking ERalpha but not ERbeta. *Mol Endocrinol*. 2003; 17(6):1039–53. [PubMed: 12624116]
62. Ohlsson C, et al. Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. *Biochem Biophys Res Commun*. 2000; 278(3):640–5. [PubMed: 11095962]
63. Walf AA, Frye CA. ERbeta-selective estrogen receptor modulators produce antianxiety behavior when administered systemically to ovariectomized rats. *Neuropsychopharmacology*. 2005; 30(9):1598–609. [PubMed: 15798780]
64. Rhodes ME, Frye CA. ERbeta-selective SERMs produce mnemonic-enhancing effects in the inhibitory avoidance and water maze tasks. *Neurobiol Learn Mem*. 2006; 85(2):183–91. [PubMed: 16326119]
65. Mazzucco CA, et al. ERalpha, but not ERbeta, mediates the expression of sexual behavior in the female rat. *Behav Brain Res*. 2008; 191(1):111–7. [PubMed: 18433893]
66. Walf AA, et al. Antisense oligodeoxynucleotides for estrogen receptor-beta and alpha attenuate estradiol's modulation of affective and sexual behavior, respectively. *Neuropsychopharmacology*. 2008; 33(2):431–40. [PubMed: 17443129]
67. Imwalle DB, Gustafsson JA, Rissman EF. Lack of functional estrogen receptor beta influences anxiety behavior and serotonin content in female mice. *Physiol Behav*. 2005; 84(1):157–63. [PubMed: 15642619]
68. Krezel W, et al. Increased anxiety and synaptic plasticity in estrogen receptor beta-deficient mice. *Proc Natl Acad Sci U S A*. 2001; 98(21):12278–82. [PubMed: 11593044]
69. Rocha BA, et al. 17 Beta-estradiol-induced antidepressant-like effect in the forced swim test is absent in estrogen receptor-beta knockout (BERKO) mice. *Psychopharmacology (Berl)*. 2005; 179(3):637–43. [PubMed: 15645223]
70. Walf AA, Koonce CJ, Frye CA. Estradiol or diarylpropionitrile decrease anxiety-like behavior of wildtype, but not estrogen receptor beta knockout, mice. *Behav Neurosci*. 2008; 122(5):974–81. [PubMed: 18823154]
71. Hughes ZA, et al. WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent. *Neuropharmacology*. 2008; 54(7):1136–42. [PubMed: 18423777]
72. Hiroi R, McDevitt RA, Neumaier JF. Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. *Biol Psychiatry*. 2006; 60(3):288–95. [PubMed: 16458260]
73. Wise DD, Felker A, Stahl SM. Tailoring treatment of depression for women across the reproductive lifecycle: the importance of pregnancy, vasomotor symptoms, and other estrogen-related events in psychopharmacology. *CNS Spectr*. 2008; 13(8):647–62. [PubMed: 18704021]
74. Walf AA, Frye CA. Administration of estrogen receptor beta-specific selective estrogen receptor modulators to the hippocampus decrease anxiety and depressive behavior of ovariectomized rats. *Pharmacol Biochem Behav*. 2007; 86(2):407–14. [PubMed: 16916539]
75. Yamaguchi-Shima N, Yuri K. Age-related changes in the expression of ER-beta mRNA in the female rat brain. *Brain Res*. 2007; 1155:34–41. [PubMed: 17490623]
76. Schulz D, et al. “Despair” induced by extinction trials in the water maze: relationship with measures of anxiety in aged and adult rats. *Neurobiol Learn Mem*. 2007; 87(3):309–23. [PubMed: 17079170]
77. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. *Mol Psychiatry*. 2002; 7(3):254–75. [PubMed: 11920153]

78. Mantella RC, et al. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. *Psychoneuroendocrinology*. 2008; 33(6):773–81. [PubMed: 18407426]
79. de Kloet CS, et al. Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review. *J Psychiatr Res*. 2006; 40(6): 550–67. [PubMed: 16214171]
80. Herman JP, et al. Limbic system mechanisms of stress regulation: hypothalamo-pituitary-adrenocortical axis. *Prog Neuropsychopharmacol Biol Psychiatry*. 2005; 29(8):1201–13. [PubMed: 16271821]
81. McQuade R, Young AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. *Br J Psychiatry*. 2000; 177:390–5. [PubMed: 11059990]
82. Kompagne H, et al. Chronic mild stress generates clear depressive but ambiguous anxiety-like behaviour in rats. *Behav Brain Res*. 2008; 193(2):311–4. [PubMed: 18590771]
83. Ueyama T, et al. Estrogen alters c-Fos response to immobilization stress in the brain of ovariectomized rats. *Brain Res*. 2006; 1084(1):67–79. [PubMed: 16545785]
84. Gronli J, et al. Effects of chronic mild stress on sexual behavior, locomotor activity and consumption of sucrose and saccharine solutions. *Physiol Behav*. 2005; 84(4):571–7. [PubMed: 15811392]
85. Choi DC, et al. The anteroventral bed nucleus of the stria terminalis differentially regulates hypothalamic-pituitary-adrenocortical axis responses to acute and chronic stress. *Endocrinology*. 2008; 149(2):818–26. [PubMed: 18039788]
86. Becker C, et al. Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin. *Mol Psychiatry*. 2008; 13(12):1079–92. [PubMed: 17893702]
87. Huhman KL, et al. Conditioned defeat in male and female Syrian hamsters. *Horm Behav*. 2003; 44(3):293–9. [PubMed: 14609551]
88. Lunga P, Herbert J. 17Beta-oestradiol modulates glucocorticoid, neural and behavioural adaptations to repeated restraint stress in female rats. *J Neuroendocrinol*. 2004; 16(9):776–85. [PubMed: 15344916]
89. Marvan ML, et al. Inescapable shocks accentuate fluctuations of forced swimming immobility in different phases of the rat estrous cycle. *Arch Med Res*. 1997; 28(3):369–72. [PubMed: 9291632]
90. Marvan ML, Chavez-Chavez L, Santana S. Clomipramine modifies fluctuations of forced swimming immobility in different phases of the rat estrous cycle. *Arch Med Res*. 1996; 27(1):83–6. [PubMed: 8867373]
91. Jenkins JA, et al. The influence of gender and the estrous cycle on learned helplessness in the rat. *Biol Psychol*. 2001; 58(2):147–58. [PubMed: 11600242]
92. Shors TJ, et al. Stages of estrous mediate the stress-induced impairment of associative learning in the female rat. *Neuroreport*. 1998; 9(3):419–23. [PubMed: 9512383]
93. Wood GE, Shors TJ. Stress facilitates classical conditioning in males, but impairs classical conditioning in females through activational effects of ovarian hormones. *Proc Natl Acad Sci U S A*. 1998; 95(7):4066–71. [PubMed: 9520494]
94. Louvart H, et al. Effects of a single footshock followed by situational reminders on HPA axis and behaviour in the aversive context in male and female rats. *Psychoneuroendocrinology*. 2006; 31(1):92–9. [PubMed: 16081221]
95. Renard GM, et al. Sex differences in rats: effects of chronic stress on sympathetic system and anxiety. *Physiol Behav*. 2005; 85(3):363–9. [PubMed: 15939444]
96. Westenbroek C, Den Boer JA, Ter Horst GJ. Gender-specific effects of social housing on chronic stress-induced limbic Fos expression. *Neuroscience*. 2003; 121(1):189–99. [PubMed: 12946711]
97. Bowman RE, et al. Aged rats: sex differences and responses to chronic stress. *Brain Res*. 2006; 1126(1):156–66. [PubMed: 16919611]
98. Steenbergen HL, et al. Sex-dependent effects of inescapable shock administration on shuttlebox-escape performance and elevated plus-maze behavior. *Physiol Behav*. 1990; 48(4):571–6. [PubMed: 2075210]

99. Steenbergen HL, et al. Sex-dependent effects of inescapable shock administration on behavior and subsequent escape performance in rats. *Physiol Behav.* 1989; 45(4):781–7. [PubMed: 2780848]
100. Heinsbroek RP, et al. Sex differences in response rates during random ratio acquisition: effects of gonadectomy. *Physiol Behav.* 1987; 39(2):269–72. [PubMed: 3575464]
101. Kennett GA, et al. Female rats are more vulnerable than males in an animal model of depression: the possible role of serotonin. *Brain Res.* 1986; 382(2):416–21. [PubMed: 3756525]
102. Mathews IZ, et al. Increased depressive behaviour in females and heightened corticosterone release in males to swim stress after adolescent social stress in rats. *Behav Brain Res.* 2008; 190(1):33–40. [PubMed: 18342957]
103. Renard GM, Rivarola MA, Suarez MM. Sexual dimorphism in rats: effects of early maternal separation and variable chronic stress on pituitary-adrenal axis and behavior. *Int J Dev Neurosci.* 2007; 25(6):373–9. [PubMed: 17764866]
104. Van Oyen HGV, Van de Poll NE, De Bruin JPC. Sex age and shock-intensity as factors in passive avoidance. *Physiol Behav.* 1979; 23:915–8. [PubMed: 523547]
105. Beatty WW, Beatty PA. Hormonal determinants of sex differences in avoidance behavior and reactivity to electric shock in the rat. *J Comp Physiol Psychol.* 1970; 73(3):446–55. [PubMed: 5514680]
106. Denti A, Epstein A. Sex differences in the acquisition of two kinds of avoidance behavior in rats. *Physiol Behav.* 1972; 8(4):611–5. [PubMed: 5064522]
107. Van Haaren FV. Effect of light intensity on passive avoidance behavior of male and female wistar rats. *Physiol Behav.* 1986; 36(1):123–5. [PubMed: 3952170]
108. Young EA. Sex differences in response to exogenous corticosterone: a rat model of hypercortisolemia. *Mol Psychiatry.* 1996; 1(4):313–9. [PubMed: 9118357]
109. Critchlow V, et al. Sex difference in resting pituitary-adrenal function in the rat. *Am J Physiol.* 1963; 205(5):807–15. [PubMed: 4291060]
110. Kitay JI. Sex differences in adrenal cortical secretion in the rat. *Endocrinology.* 1961; 68:818–24. [PubMed: 13756461]
111. Walker QD, et al. Effect of ovarian hormones and estrous cycle on stimulation of the hypothalamo-pituitary-adrenal axis by cocaine. *J Pharmacol Exp Ther.* 2001; 297(1):291–8. [PubMed: 11259556]
112. Carey MP, et al. The influence of ovarian steroids on hypothalamic-pituitary-adrenal regulation in the female rat. *J Endocrinol.* 1995; 144(2):311–21. [PubMed: 7706984]
113. Viau V, Meaney MJ. Variations in the hypothalamic-pituitary-adrenal response to stress during the estrous cycle in the rat. *Endocrinology.* 1991; 129(5):2503–11. [PubMed: 1657578]
114. Viau V, Meaney MJ. Alpha1 adrenoreceptors mediate the stimulatory effects of oestrogen on stress-related hypothalamic-pituitary-adrenal activity in the female rat. *J Neuroendocrinol.* 2004; 16(1):72–8. [PubMed: 14962079]
115. Figueiredo HF, Dolgas CM, Herman JP. Stress activation of cortex and hippocampus is modulated by sex and stage of estrus. *Endocrinology.* 2002; 143(7):2534–40. [PubMed: 12072385]
116. Brunton PJ, Russell JA. Attenuated hypothalamo-pituitary-adrenal axis responses to immune challenge during pregnancy: the neurosteroid opioid connection. *J Physiol.* 2008; 586(2):369–75. [PubMed: 17991694]
117. Toufexis DJ, Walker CD. Noradrenergic facilitation of the adrenocorticotropin response to stress is absent during lactation in the rat. *Brain Res.* 1996; 737(1–2):71–7. [PubMed: 8930352]
118. Windle RJ, et al. Endocrine and behavioural responses to noise stress: comparison of virgin and lactating female rats during non-disrupted maternal activity. *J Neuroendocrinol.* 1997; 9(6):407–14. [PubMed: 9229351]
119. Lightman SL, et al. Peripartum plasticity within the hypothalamo-pituitary-adrenal axis. *Prog Brain Res.* 2001; 133:111–29. [PubMed: 11589125]
120. Russell JA, Leng G, Douglas AJ. The magnocellular oxytocin system, the fount of maternity: adaptations in pregnancy. *Front Neuroendocrinol.* 2003; 24(1):27–61. [PubMed: 12609499]

121. Chiodera P, et al. Relationship between plasma profiles of oxytocin and adrenocorticotrophic hormone during suckling or breast stimulation in women. *Horm Res.* 1991; 35(3–4):119–23. [PubMed: 1666892]
122. Burgess LH, Handa RJ. Chronic estrogen-induced alterations in adrenocorticotropin and corticosterone secretion, and glucocorticoid receptor-mediated functions in female rats. *Endocrinology.* 1992; 131(3):1261–9. [PubMed: 1324155]
123. Handa RJ, et al. Gonadal steroid hormone receptors and sex differences in the hypothalamo-pituitary-adrenal axis. *Horm Behav.* 1994; 28(4):464–76. [PubMed: 7729815]
124. Figueiredo HF, et al. Estrogen potentiates adrenocortical responses to stress in female rats. *Am J Physiol Endocrinol Metab.* 2007; 292(4):E1173–1182. [PubMed: 17179393]
125. Young EA, et al. Effects of estrogen antagonists and agonists on the ACTH response to restraint stress in female rats. *Neuropsychopharmacology.* 2001; 25(6):881–91. [PubMed: 11750181]
126. Redei E, et al. Fast glucocorticoid feedback inhibition of ACTH secretion in the ovariectomized rat: effect of chronic estrogen and progesterone. *Neuroendocrinology.* 1994; 60(2):113–23. [PubMed: 7969768]
127. Bohler HC Jr, et al. Corticotropin releasing hormone mRNA is elevated on the afternoon of proestrus in the parvocellular paraventricular nuclei of the female rat. *Brain Res Mol Brain Res.* 1990; 8(3):259–62. [PubMed: 2170804]
128. Lund TD, et al. Androgen inhibits, while oestrogen enhances, restraint-induced activation of neuropeptide neurones in the paraventricular nucleus of the hypothalamus. *J Neuroendocrinol.* 2004; 16(3):272–8. [PubMed: 15049858]
129. Patchev VK, et al. Implications of estrogen-dependent brain organization for gender differences in hypothalamo-pituitary-adrenal regulation. *Faseb J.* 1995; 9(5):419–23. [PubMed: 7896013]
130. Vamvakopoulos NC, Chrousos GP. Evidence of direct estrogenic regulation of human corticotropin-releasing hormone gene expression. Potential implications for the sexual dimorphism of the stress response and immune/inflammatory reaction. *J Clin Invest.* 1993; 92(4):1896–902. [PubMed: 8408641]
131. Haas DA, George SR. Gonadal regulation of corticotropin-releasing factor immunoreactivity in hypothalamus. *Brain Res Bull.* 1988; 20(3):361–7. [PubMed: 3284608]
132. Dayas CV, et al. Effects of chronic oestrogen replacement on stress-induced activation of hypothalamic-pituitary-adrenal axis control pathways. *J Neuroendocrinol.* 2000; 12(8):784–94. [PubMed: 10929091]
133. Lund TD, et al. Novel actions of estrogen receptor-beta on anxiety-related behaviors. *Endocrinology.* 2005; 146(2):797–807. [PubMed: 15514081]
134. Lund TD, Hinds LR, Handa RJ. The androgen 5alpha-dihydrotestosterone and its metabolite 5alpha-androstan-3beta,17beta-diol inhibit the hypothalamo-pituitary-adrenal response to stress by acting through estrogen receptor beta-expressing neurons in the hypothalamus. *J Neurosci.* 2006; 26(5):1448–56. [PubMed: 16452668]
135. Dalla C, et al. Chronic mild stress impact: are females more vulnerable? *Neuroscience.* 2005; 135(3):703–14. [PubMed: 16125862]
136. Duncko R, et al. Corticotropin-releasing hormone mRNA levels in response to chronic mild stress rise in male but not in female rats while tyrosine hydroxylase mRNA levels decrease in both sexes. *Psychoneuroendocrinology.* 2001; 26(1):77–89. [PubMed: 11070336]
137. Galea LA, et al. Sex differences in dendritic atrophy of CA3 pyramidal neurons in response to chronic restraint stress. *Neuroscience.* 1997; 81(3):689–97. [PubMed: 9316021]
138. Konkle AT, et al. Evaluation of the effects of chronic mild stressors on hedonic and physiological responses: sex and strain compared. *Brain Res.* 2003; 992(2):227–38. [PubMed: 14625061]
139. Gerrits M, et al. Cyclic estradiol replacement attenuates stress-induced c-Fos expression in the PVN of ovariectomized rats. *Brain Res Bull.* 2005; 67(1–2):147–55. [PubMed: 16140174]
140. Gerrits M, et al. Stress-induced sensitization of the limbic system in ovariectomized rats is partly restored by cyclic 17beta-estradiol administration. *Eur J Neurosci.* 2006; 23(7):1747–56. [PubMed: 16623831]
141. Aihara M, et al. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal

- cortex and limbic/paralimbic regions. *Psychiatry Res.* 2007; 155(3):245–56. [PubMed: 17587554]
142. Young EA, et al. Alteration in the hypothalamic-pituitary-ovarian axis in depressed women. *Arch Gen Psychiatry.* 2000; 57(12):1157–62. [PubMed: 11115329]
 143. Chrousos GP, Torpy DJ, Gold PW. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. *Ann Intern Med.* 1998; 129(3):229–40. [PubMed: 9696732]
 144. Kalantaridou SN, et al. Stress and the female reproductive system. *J Reprod Immunol.* 2004; 62(1–2):61–8. [PubMed: 15288182]
 145. Grippo AJ, et al. Chronic mild stress induces behavioral and physiological changes, and may alter serotonin 1A receptor function, in male and cycling female rats. *Psychopharmacology (Berl).* 2005; 179(4):769–80. [PubMed: 15619113]
 146. Baker SL, et al. Behavioral and physiological effects of chronic mild stress in female rats. *Physiol Behav.* 2006; 87(2):314–22. [PubMed: 16386277]
 147. Blanchard DC, et al. Visible burrow system as a model of chronic social stress: behavioral and neuroendocrine correlates. *Psychoneuroendocrinology.* 1995; 20(2):117–34. [PubMed: 7899533]
 148. Almeida OP, et al. Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. *Arch Gen Psychiatry.* 2008; 65(3):283–9. [PubMed: 18316674]
 149. Fernandez-Guasti A, Martinez-Mota L. Anxiolytic-like actions of testosterone in the burying behavior test: role of androgen and GABA-benzodiazepine receptors. *Psychoneuroendocrinology.* 2005; 30(8):762–70. [PubMed: 15919582]
 150. Isgor C, et al. Estrogen receptor beta in the paraventricular nucleus of hypothalamus regulates the neuroendocrine response to stress and is regulated by corticosterone. *Neuroscience.* 2003; 121(4):837–45. [PubMed: 14580933]
 151. Suzuki S, Handa RJ. Regulation of estrogen receptor-beta expression in the female rat hypothalamus: differential effects of dexamethasone and estradiol. *Endocrinology.* 2004; 145(8):3658–70. [PubMed: 15087431]
 152. Barros HM, Ferigolo M. Ethopharmacology of imipramine in the forced-swimming test: gender differences. *Neurosci Biobehav Rev.* 1998; 23(2):279–86. [PubMed: 9884121]
 153. Campbell T, et al. Coping strategies in male and female rats exposed to multiple stressors. *Physiol Behav.* 2003; 78(3):495–504. [PubMed: 12676287]
 154. Zimmerberg B, et al. Differences in affective behaviors and hippocampal allopregnanolone levels in adult rats of lines selectively bred for infantile vocalizations. *Behav Brain Res.* 2005; 159(2):301–11. [PubMed: 15817193]
 155. Gray JA, Buffery AW. Sex differences in emotional and cognitive behaviour in mammals including man: adaptive and neural bases. *Acta Psychol (Amst).* 1971; 35(2):89–111. [PubMed: 5552802]
 156. Gray JA. Emotionality in male and female rodents: a reply to Archer. *Br J Psychol.* 1979; 70(3):425–40. [PubMed: 486879]
 157. Haller J, et al. Defeat is a major stressor in males while social instability is stressful mainly in females: towards the development of a social stress model in female rats. *Brain Res Bull.* 1999; 50(1):33–9. [PubMed: 10507469]
 158. Patisaul HB, Burke KT, Hinkle RE, Adewale HB, Shea D. Systemic administration of diarylpropionitrile (DPN) or phytoestrogens does not affect anxiety-related behaviors in gonadally intact male rats. *Horm Behav.* Feb; 2009 55(2):319–28. [Epub 2008 Nov 21]. [PubMed: 19071129]

Fig. 1.

Schematic diagram of the HPA axis. CRH (corticotropin releasing hormone) and AVP (arginine vasopressin) released from the medial parvocellular division of the PVN (paraventricular nucleus of the hypothalamus) stimulates the anterior pituitary resulting in the release of ACTH (adrenocorticotropin hormone). ACTH travels through the circulatory system, stimulating the adrenal cortex and resulting in the synthesis and release of glucocorticoids. Glucocorticoids exert negative feedback at the level of the pituitary, adrenals, hypothalamic and upstream extra-hypothalamic areas including the mPFC (medial prefrontal cortex) and HIPP (hippocampus), preventing prolonged activation of the system. Reduced feedback is thought to accompany mood disorders, resulting in amplified glucocorticoid signaling in the brain. Solid lines are stimulatory and dashed lines are inhibitory.

Fig. 2.

Schematic diagram illustrating how physiological doses of estradiol (E₂), presumably signaling through ER β , can decrease stress-induced activation. During periods of prolonged stress, E₂ increases activation in upstream inhibitory regions such as the mPFC, thereby increasing inhibitory outflow from the mPFC to the PVN, resulting in decreased CRH and AVP release from the PVN. The net result is a decreased ACTH from the anterior pituitary. Solid lines are stimulatory and dashed lines are inhibitory.